 Connection
Craig Friesen to Antibodies, Monoclonal
This is a "connection" page, showing publications Craig Friesen has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.248 |
|
|
|
-
Turner D, Friesen C. Authors' response. J Pediatr Gastroenterol Nutr. 2013 Oct; 57(4):e25-6.
Score: 0.474
-
Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, Ngan B, Friesen C. Anti-TNF, infliximab, and adalimumab can be effective in eosinophilic bowel disease. J Pediatr Gastroenterol Nutr. 2013 May; 56(5):492-7.
Score: 0.460
-
Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004 Sep; 39(3):265-9.
Score: 0.253
-
Carpenter E, Jackson MA, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J Pediatr. 2004 Apr; 144(4):541-4.
Score: 0.061
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|